The outgoing chief executive of the UK’s drugs regulator has said that the country’s “preferred option” is to continue working with the European regulator after Brexit – although there are
With a Brexit deal still out of sight, there have been intensified warnings in the UK about potential disruptions to medicine supplies that could follow a no-deal scenario.
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has convened an Expert Working Group (EWG) to assess the risks and benefits of opioid medicines and see if current UK reg
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.